title: Improving the drug selection and development process for combination devices.
abstract: Combination devices are at the interface of both pharmaceutical and medical device research. While there have been several notable successes in bringing combination devices to market there are drug selection criteria that both the pharmaceutical and medical device companies need to consider. A successful combination device creates a product that has efficacy greater than the sum of the parts. However, failure to address some aspects of the drug or biologic properties in enough detail could result in a suboptimal product, creating a challenging legacy for future iterations. This review addresses the many dimensions including opportunities and challenges of combination device development from both the device and pharmaceutical perspectives.
authors.affiliation: PA Consulting Group, 600 College Road East, Suite 1120, Princeton, NJ 08540, USA. maggie.hupcey@paconsulting.com
authors.forename: Maggie A Z
authors.initials: MA
authors.lastname: Hupcey
authors.forename: Sean
authors.initials: S
authors.lastname: Ekins
mesh_terms: D016503:Drug Delivery Systems / Q000009:adverse effects / Q000295:instrumentation; D004343:Drug Implants; D004345:Drug Industry; D054855:Drug-Eluting Stents / Q000009:adverse effects; D004867:Equipment Design; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D019736:Prostheses and Implants / Q000009:adverse effects; D012107:Research Design; D013673:Technology Assessment, Biomedical
chemical_list: D004343:Drug Implants; D004364:Pharmaceutical Preparations